This page has only limited features, please log in for full access.

Dr. Elizabeth Fry
Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Basic Info

Basic Info is private.

Research Keywords & Expertise

0 X-ray crystallography
0 Immune response
0 Picornaviruses
0 viral entry
0 Vaccine development

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Preprint content
Published: 13 June 2020 in bioRxiv
Reads 0
Downloads 0

The COVID-19 pandemic has had unprecedented health and economic impact, but currently there are no approved therapies. We have isolated an antibody, EY6A, from a late-stage COVID-19 patient and show it neutralises SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds tightly (KD of 2 nM) the receptor binding domain (RBD) of the viral Spike glycoprotein and a 2.6Å crystal structure of an RBD/EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues of this epitope are key to stabilising the pre-fusion Spike. Cryo-EM analyses of the pre-fusion Spike incubated with EY6A Fab reveal a complex of the intact trimer with three Fabs bound and two further multimeric forms comprising destabilized Spike attached to Fab. EY6A binds what is probably a major neutralising epitope, making it a candidate therapeutic for COVID-19.

ACS Style

Daming Zhou; Helen M E Duyvesteyn; Cheng-Pin Chen; Chung-Guei Huang; Ting-Hua Chen; Shin-Ru Shih; Yi-Chun Lin; Chien-Yu Cheng; Shu-Hsing Cheng; Yhu-Chering Huang; Tzou-Yien Lin; Che Ma; Jiandong Huo; Loic Carrique; Tomas Malinauskas; Reinis R Ruza; Pranav Nm Shah; Tiong Kit Tan; Pramila Rijal; Robert F. Donat; Kerry Godwin; Karen Buttigieg; Julia Tree; Julika Radecke; Neil G Paterson; Piyasa Supasa; Juthathip Mongkolsapaya; Gavin R Screaton; Miles W. Carroll; Javier G. Jaramillo; Michael Knight; William S James; Raymond J Owens; James H. Naismith; Alain Townsend; Elizabeth E Fry; Yuguang Zhao; Jingshan Ren; David I Stuart; Kuan-Ying A. Huang. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. bioRxiv 2020, 1 .

AMA Style

Daming Zhou, Helen M E Duyvesteyn, Cheng-Pin Chen, Chung-Guei Huang, Ting-Hua Chen, Shin-Ru Shih, Yi-Chun Lin, Chien-Yu Cheng, Shu-Hsing Cheng, Yhu-Chering Huang, Tzou-Yien Lin, Che Ma, Jiandong Huo, Loic Carrique, Tomas Malinauskas, Reinis R Ruza, Pranav Nm Shah, Tiong Kit Tan, Pramila Rijal, Robert F. Donat, Kerry Godwin, Karen Buttigieg, Julia Tree, Julika Radecke, Neil G Paterson, Piyasa Supasa, Juthathip Mongkolsapaya, Gavin R Screaton, Miles W. Carroll, Javier G. Jaramillo, Michael Knight, William S James, Raymond J Owens, James H. Naismith, Alain Townsend, Elizabeth E Fry, Yuguang Zhao, Jingshan Ren, David I Stuart, Kuan-Ying A. Huang. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. bioRxiv. 2020; ():1.

Chicago/Turabian Style

Daming Zhou; Helen M E Duyvesteyn; Cheng-Pin Chen; Chung-Guei Huang; Ting-Hua Chen; Shin-Ru Shih; Yi-Chun Lin; Chien-Yu Cheng; Shu-Hsing Cheng; Yhu-Chering Huang; Tzou-Yien Lin; Che Ma; Jiandong Huo; Loic Carrique; Tomas Malinauskas; Reinis R Ruza; Pranav Nm Shah; Tiong Kit Tan; Pramila Rijal; Robert F. Donat; Kerry Godwin; Karen Buttigieg; Julia Tree; Julika Radecke; Neil G Paterson; Piyasa Supasa; Juthathip Mongkolsapaya; Gavin R Screaton; Miles W. Carroll; Javier G. Jaramillo; Michael Knight; William S James; Raymond J Owens; James H. Naismith; Alain Townsend; Elizabeth E Fry; Yuguang Zhao; Jingshan Ren; David I Stuart; Kuan-Ying A. Huang. 2020. "Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient." bioRxiv , no. : 1.